Franco Folli

Summary

Publications

  1. Urbani A, De Canio M, Palmieri F, Sechi S, Bini L, Castagnola M, et al. The mitochondrial Italian Human Proteome Project initiative (mt-HPP). Mol Biosyst. 2013;9:1984-92 pubmed publisher
    ....
  2. Tripathy D, Daniele G, Fiorentino T, Perez Cadena Z, Chavez Velasquez A, Kamath S, et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia. 2013;56:2153-63 pubmed publisher
    ..Low-dose PIO (15 mg/day) improves glycaemic control, beta cell function and inflammatory state in obese patients with type 2 diabetes. Clinical.Trial.gov NCT01223196. This study was funded by TAKEDA. ..
  3. Andreozzi F, Raciti G, Nigro C, Mannino G, Procopio T, Davalli A, et al. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. J Transl Med. 2016;14:229 pubmed publisher
    ..Finally, EXE also induces glucose transporter Glut-4 translocation to the plasma membrane. In L6 myotubes, EXE and liraglutide increase glucose uptake in an insulin-independent manner by activating AMPK. ..
  4. Folli F, Okada T, Perego C, Gunton J, Liew C, Akiyama M, et al. Altered insulin receptor signalling and ?-cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE. 2011;6:e28050 pubmed publisher
    ..Activation of insulin signaling, FoxO1 and proteins in ?-cell-cycle progression are attractive therapeutic targets to enhance ?-cell regeneration in the treatment of T2DM. ..
  5. Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care. 2015;38:1509-17 pubmed publisher
    ..The correlation between sclerostin and insulin clearance at fasting state and during OGTT is novel; thus, studies are needed to explore the potential causal relationship. ..
  6. Folli F, Sabowitz B, Schwesinger W, Fanti P, Guardado Mendoza R, Muscogiuri G. Bariatric surgery and bone disease: from clinical perspective to molecular insights. Int J Obes (Lond). 2012;36:1373-9 pubmed publisher
    ..Further, we suggest a future research agenda. ..

Detail Information

Publications6

  1. Urbani A, De Canio M, Palmieri F, Sechi S, Bini L, Castagnola M, et al. The mitochondrial Italian Human Proteome Project initiative (mt-HPP). Mol Biosyst. 2013;9:1984-92 pubmed publisher
    ....
  2. Tripathy D, Daniele G, Fiorentino T, Perez Cadena Z, Chavez Velasquez A, Kamath S, et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia. 2013;56:2153-63 pubmed publisher
    ..Low-dose PIO (15 mg/day) improves glycaemic control, beta cell function and inflammatory state in obese patients with type 2 diabetes. Clinical.Trial.gov NCT01223196. This study was funded by TAKEDA. ..
  3. Andreozzi F, Raciti G, Nigro C, Mannino G, Procopio T, Davalli A, et al. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. J Transl Med. 2016;14:229 pubmed publisher
    ..Finally, EXE also induces glucose transporter Glut-4 translocation to the plasma membrane. In L6 myotubes, EXE and liraglutide increase glucose uptake in an insulin-independent manner by activating AMPK. ..
  4. Folli F, Okada T, Perego C, Gunton J, Liew C, Akiyama M, et al. Altered insulin receptor signalling and ?-cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE. 2011;6:e28050 pubmed publisher
    ..Activation of insulin signaling, FoxO1 and proteins in ?-cell-cycle progression are attractive therapeutic targets to enhance ?-cell regeneration in the treatment of T2DM. ..
  5. Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care. 2015;38:1509-17 pubmed publisher
    ..The correlation between sclerostin and insulin clearance at fasting state and during OGTT is novel; thus, studies are needed to explore the potential causal relationship. ..
  6. Folli F, Sabowitz B, Schwesinger W, Fanti P, Guardado Mendoza R, Muscogiuri G. Bariatric surgery and bone disease: from clinical perspective to molecular insights. Int J Obes (Lond). 2012;36:1373-9 pubmed publisher
    ..Further, we suggest a future research agenda. ..